159 related articles for article (PubMed ID: 11274244)
21. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T
Nephron; 2002 Mar; 90(3):256-61. PubMed ID: 11867945
[TBL] [Abstract][Full Text] [Related]
22. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients.
Sennesael J; Lamote J; Violet I; Tasse S; Verbeelen D
Hypertension; 1995 Sep; 26(3):436-44. PubMed ID: 7649579
[TBL] [Abstract][Full Text] [Related]
23. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Hiltunen TP; Suonsyrjä T; Hannila-Handelberg T; Paavonen KJ; Miettinen HE; Strandberg T; Tikkanen I; Tilvis R; Pentikäinen PJ; Virolainen J; Kontula K
Am J Hypertens; 2007 Mar; 20(3):311-8. PubMed ID: 17324745
[TBL] [Abstract][Full Text] [Related]
24. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.
Hong BK; Park CG; Kim KS; Yoon MH; Yoon HJ; Yoon JH; Yang JY; Choi YJ; Cho SY
Am J Cardiovasc Drugs; 2012 Jun; 12(3):189-95. PubMed ID: 22462558
[TBL] [Abstract][Full Text] [Related]
26. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
27. Control of home blood pressure with an amlodipine- or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy.
Ohta Y; Kawano Y; Iwashima Y; Hayashi S; Yoshihara F; Matayoshi T; Takiuchi S; Kamide K; Nakamura S; Horio T
Clin Exp Hypertens; 2013; 35(4):279-84. PubMed ID: 23530977
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effects of amlodipine and losartan on 24-hour ambulatory blood pressure in hypertensive patients.
Ishimitsu T; Minami J; Yoshii M; Suzuki T; Inada H; Ohta S; Futoh Y; Ono H; Matsuoka H
Clin Exp Hypertens; 2002; 24(1-2):41-50. PubMed ID: 11848168
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor beta in hypertensives with cardiorenal damage.
Laviades C; Varo N; Díez J
Hypertension; 2000 Oct; 36(4):517-22. PubMed ID: 11040229
[TBL] [Abstract][Full Text] [Related]
30. Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats.
Yu G; Liang X; Xie X; Su M; Zhao S
Int J Cardiol; 2001 Dec; 81(2-3):123-9; discussion 129-30. PubMed ID: 11744126
[TBL] [Abstract][Full Text] [Related]
31. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.
Lavoie P; Robitaille G; Agharazii M; Ledbetter S; Lebel M; Larivière R
J Hypertens; 2005 Oct; 23(10):1895-903. PubMed ID: 16148614
[TBL] [Abstract][Full Text] [Related]
32. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients.
Wu SC; Liu CP; Chiang HT; Lin SL
Heart Vessels; 2004 Jan; 19(1):13-8. PubMed ID: 14685749
[TBL] [Abstract][Full Text] [Related]
33. Renal effects of amlodipine in normotensive renal transplant recipients.
Venkat Raman G; Feehally J; Coates RA; Elliott HL; Griffin PJ; Olubodun JO; Wilkinson R
Nephrol Dial Transplant; 1999 Feb; 14(2):384-8. PubMed ID: 10069193
[TBL] [Abstract][Full Text] [Related]
34. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
Houlihan CA; Akdeniz A; Tsalamandris C; Cooper ME; Jerums G; Gilbert RE
Diabetes Care; 2002 Jun; 25(6):1072-7. PubMed ID: 12032117
[TBL] [Abstract][Full Text] [Related]
35. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
Mas VR; Alvarellos T; Maluf DG; Ferreira-Gonzalez A; Oliveros L; Maldonado RA; de Boccardo G
Transpl Int; 2004 Oct; 17(9):540-4. PubMed ID: 15349718
[TBL] [Abstract][Full Text] [Related]
36. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Coto E; Marín R; Alvarez V; Praga M; Fernández Andrade C; Arias M; Poveda R; Vallés M; Galcerán JM; Luño J; Rivera F; Campistol JM
Nefrologia; 2005; 25(4):381-6. PubMed ID: 16231503
[TBL] [Abstract][Full Text] [Related]
38. Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Chen J; Gu Y; Lin F; Yang H; Zhu W; Ma J; Lin S
Chin Med J (Engl); 2002 Jul; 115(7):972-8. PubMed ID: 12150723
[TBL] [Abstract][Full Text] [Related]
39. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group.
Wilson TW; Lacourcière Y; Barnes CC
CMAJ; 1998 Sep; 159(5):469-76. PubMed ID: 9757170
[TBL] [Abstract][Full Text] [Related]
40. Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
Epstein M; Hollenberg NK
Am J Hypertens; 2004 Jul; 17(7):638-9; author reply 639-40. PubMed ID: 15233985
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
